BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 29220539)

  • 21. [EEF1A2 inhibits the p53 function in hepatocellular carcinoma via PI3K/AKT/mTOR-dependent stabilization of MDM4].
    Longerich T
    Pathologe; 2014 Nov; 35 Suppl 2():177-84. PubMed ID: 25394965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
    Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
    EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emodin succinyl ester inhibits malignant proliferation and migration of hepatocellular carcinoma by suppressing the interaction of AR and EZH2.
    Khan H; Jia W; Yu Z; Zaib T; Feng J; Jiang Y; Song H; Bai Y; Yang B; Feng H
    Biomed Pharmacother; 2020 Aug; 128():110244. PubMed ID: 32464306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
    Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
    J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer.
    Audet-Walsh É; Dufour CR; Yee T; Zouanat FZ; Yan M; Kalloghlian G; Vernier M; Caron M; Bourque G; Scarlata E; Hamel L; Brimo F; Aprikian AG; Lapointe J; Chevalier S; Giguère V
    Genes Dev; 2017 Jun; 31(12):1228-1242. PubMed ID: 28724614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. USP10 suppresses tumor progression by inhibiting mTOR activation in hepatocellular carcinoma.
    Lu C; Ning Z; Wang A; Chen D; Liu X; Xia T; Tekcham DS; Wang W; Li T; Liu X; Liu J; Qi H; Luo H; Du J; Ma C; Yan Q; Liu J; Xu G; Piao HL; Tan G
    Cancer Lett; 2018 Nov; 436():139-148. PubMed ID: 30056112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The androgen receptor antagonist enzalutamide induces apoptosis, dysregulates the heat shock protein system, and diminishes the androgen receptor and estrogen receptor β1 expression in prostate cancer cells.
    Abazid A; Martin B; Choinowski A; McNeill RV; Brandenburg LO; Ziegler P; Zimmermann U; Burchardt M; Erb H; Stope MB
    J Cell Biochem; 2019 Oct; 120(10):16711-16722. PubMed ID: 31297844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β-catenin-EGFR-PI3K-Akt-mTOR signaling pathway.
    Zhang B; Deng C; Wang L; Zhou F; Zhang S; Kang W; Zhan P; Chen J; Shen S; Guo H; Zhang M; Wang Y; Zhang F; Zhang W; Xiao J; Kong B; Friess H; Zhuge Y; Yan H; Zou X
    Mol Carcinog; 2018 Feb; 57(2):201-215. PubMed ID: 29027712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer.
    Robles AJ; Cai S; Cichewicz RH; Mooberry SL
    Breast Cancer Res Treat; 2016 Jun; 157(3):475-88. PubMed ID: 27255535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma progression by activating mTOR signaling pathway.
    Liu H; Wang X; Feng B; Tang L; Li W; Zheng X; Liu Y; Peng Y; Zheng G; He Q
    BMC Cancer; 2018 Jun; 18(1):661. PubMed ID: 29914442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen receptor functions as a negative transcriptional regulator of DEPTOR, mTOR inhibitor.
    Kanno Y; Zhao S; Yamashita N; Yanai K; Nemoto K; Inouye Y
    J Toxicol Sci; 2015 Dec; 40(6):753-8. PubMed ID: 26558456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of Hepatocellular Carcinoma in Men and the Contribution of Androgen and its Receptor in Pathogenesis and Therapy.
    Abdel-Hamid NM; Al-Quzweny RM
    Curr Mol Pharmacol; 2023; 16(5):559-563. PubMed ID: 36221879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenformin-Induced Mitochondrial Dysfunction Sensitizes Hepatocellular Carcinoma for Dual Inhibition of mTOR.
    Veiga SR; Ge X; Mercer CA; Hernández-Álvarez MI; Thomas HE; Hernandez-Losa J; Ramón Y Cajal S; Zorzano A; Thomas G; Kozma SC
    Clin Cancer Res; 2018 Aug; 24(15):3767-3780. PubMed ID: 29691292
    [No Abstract]   [Full Text] [Related]  

  • 35. Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway.
    Ma X; Guo P; Qiu Y; Mu K; Zhu L; Zhao W; Li T; Han L
    Oncotarget; 2016 Jun; 7(24):36185-36197. PubMed ID: 27167192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling.
    Liu F; Zhang W; Yang F; Feng T; Zhou M; Yu Y; Yu X; Zhao W; Yi F; Tang W; Lu Y
    Sci Rep; 2016 Feb; 6():21260. PubMed ID: 26879559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Research advances in the mammalian target of rapamycin signaling pathway and its inhibitors in treatment of hepatocellular carcinoma].
    Li SZ; Xu F; Sun CQ; Xu P
    Zhonghua Gan Zang Bing Za Zhi; 2018 Jan; 26(1):77-80. PubMed ID: 29804369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive analysis of microRNA-regulated protein interaction network reveals the tumor suppressive role of microRNA-149 in human hepatocellular carcinoma via targeting AKT-mTOR pathway.
    Zhang Y; Guo X; Xiong L; Yu L; Li Z; Guo Q; Li Z; Li B; Lin N
    Mol Cancer; 2014 Nov; 13():253. PubMed ID: 25424347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer.
    Anestis A; Sarantis P; Theocharis S; Zoi I; Tryfonopoulos D; Korogiannos A; Koumarianou A; Xingi E; Thomaidou D; Kontos M; Papavassiliou AG; Karamouzis MV
    J Cancer Res Clin Oncol; 2019 May; 145(5):1221-1233. PubMed ID: 30805773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
    Lin XM; Hu L; Gu J; Wang RY; Li L; Tang J; Zhang BH; Yan XZ; Zhu YJ; Hu CL; Zhou WP; Li S; Liu JF; Gonzalez FJ; Wu MC; Wang HY; Chen L
    Gastroenterology; 2017 Apr; 152(5):1187-1202. PubMed ID: 28065789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.